Who is sponsoring NCT00403481?

NCT00403481 is sponsored by Daiichi Sankyo.

What condition does NCT00403481 study?

NCT00403481 studies Hypertension.

What drugs are being tested in NCT00403481?

Interventions: olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide.

What is the status of NCT00403481?

NCT00403481 is currently COMPLETED.

Last reviewed 2016-09-28 · How we verify

A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension

NCT00403481 Phase 4 COMPLETED Results posted

This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Details

Lead sponsor	Daiichi Sankyo
Phase	Phase 4
Status	COMPLETED
Enrolment	192
Start date	2006-11
Completion	2007-12

Conditions

Hypertension

Interventions

olmesartan medoxomil
Olmesartan medoxomil plus Hydrochlorothiazide

Primary outcomes

Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM. — baseline and 12 weeks
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study.

Countries

United States